Extent of pulmonary thromboembolic disease in patients with COVID-19 on CT: relationship with pulmonary parenchymal disease

  1. C. Fang
  2. G. Garzillo
  3. B. Batohi
  4. J.T.H. Teo
  5. M. Berovic
  6. P.S. Sidhu
  7. H. Robbie

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.crad.2020.07.002
  2. ScreenIT

    SciScore for 10.1101/2020.06.01.20118505: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: This project operated under London South East Research Ethics committee (reference 18/LO/20448) approval granted to King’s Electronic Records Research Interface (KERRI) specific work on COVID-19 research, was reviewed with expert patient input on a virtual committee with Caldicott Guardian oversight.
    Consent: Patient consent was not required due to retrospective nature of the study.
    Randomizationnot detected.
    BlindingAll readers were blinded to patient clinical details and existing radiology reports.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    Statistical analysis: Statistical analysis was performed by using SPSS software (IBM, Chicago, version 23); P values < .
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    There are limitations to our study. The sample size is relatively small, and the data was collected retrospectively comprising patients admitted to hospital which result in selection bias of patients with more severe disease. In conclusion, the high incidence of PTD in COVID-19 patients with severe disease undergoing CTPA, current lack of reliable risk stratification tools and symptoms of PTD overlapping with severe COVID-19 disease, raises the question of whether more CTPA studies should be performed in the 2nd and 3rd week of the illness. Our study suggests that patients with severe disease may require follow-up for long term pulmonary fibrotic complications.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.06.01.20118505v1 on medRxiv